title: Cefotaxime as the potential cause of transient acquired von Willebrand syndrome.
abstract: Acquired von Willebrand syndrome (AvWS) is a relatively rare bleeding disorder. It has been reported in association with myeloproliferative disorders, autoimmune diseases, plasma cell dyscrasias and certain drugs. Cefotaxime is a third generation cephalosporin widely used for surgical prophylaxis and as empirical treatment of bacterial meningitis. We report a case of a transient AvWS in association with cefotaxime therapy.
authors.affiliation: Haematology Department, Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, UK. montaserhaj@yahoo.co.uk
authors.forename: M A
authors.initials: MA
authors.lastname: Haj
authors.forename: N
authors.initials: N
authors.lastname: Murch
authors.forename: D J
authors.initials: DJ
authors.lastname: Bowen
authors.forename: H I
authors.initials: HI
authors.lastname: Sati
authors.forename: A
authors.initials: A
authors.lastname: Beddal
authors.forename: A
authors.initials: A
authors.lastname: Benton
authors.forename: P
authors.initials: P
authors.lastname: Collins
mesh_terms: D000328:Adult; D002439:Cefotaxime / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D002439:Cefotaxime